The Marie-Josée and Henry R. Kravis Center for Molecular Oncology (CMO) is undertaking a unique and intensive endeavor to transform cancer care through genomic analysis of patient-derived tumors. The center serves a team of laboratory and clinical researchers at Memorial Sloan Kettering working together to translate new molecular insights into individualized therapies and diagnostic tools.
Watch our doctors and scientists discuss our bold new initiative to bring next-generation molecular analysis and precision medicine to our patients.
Established with a gift of $100 million from Marie-Josée and Henry R. Kravis Foundation, the CMO brings together researchers with many different areas of expertise — including cancer biology, pathology, bioinformatics, and systems biology — to undertake a vast, translational research program. For every type of cancer, archived tumor specimens and tissues obtained in clinical trials are comprehensively profiled using next-generation sequencing and other technologies. The molecular information of each tumor is then correlated with clinical data, including the patient’s outcome and response to therapy.
The goal of the CMO is to expedite and streamline cancer genomics research to guide cancer treatment. Ultimately our vision is to fully deliver on the promise of precision oncology and to create better treatment options for all people with cancer.
Thanks to our powerful combination of clinical and scientific resources focused exclusively on cancer, Memorial Sloan Kettering is in a unique position to reach this ambitious goal. The Marie-Josée and Henry R. Kravis Center for Molecular Oncology spans the full range of activities required to translate molecular insights into clinical innovations — from procuring and archiving patient tissues to pioneering the latest diagnostic tests and targeted therapies.